Jan Poth, SciRhom CEO

Ger­man an­ti­body com­pa­ny se­cures €63M for au­toim­mune dis­ease pro­gram

SciRhom has raised €63 mil­lion ($70 mil­lion) in a Se­ries A to ad­vance its lead mon­o­clon­al an­ti­body pro­gram through a first-in-hu­man tri­al set to start …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.